Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $100 from $99 and keeps a Buy rating on the shares. The firm noted they reported final overall survival (OS) data from the company’s Phase III ROSELLA trial in patients with platinum-resistant ovarian cancer (PROC). The data showed durability as the previously reported interim median OS improvement of 4.5 months was maintained and 2025 revenue estimates were increased with in guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics price target raised to $105 from $90 at H.C. Wainwright
- Midday Fly By: GE Aerospace reports Q4 beat, P&G reports mixed Q2
- Corcept Therapeutics rises 17.7%
- Corcept Therapeutics Phase 3 ROSELLA Trial Achieves Survival Benefit
- Corcept Therapeutics reports ROSELLA trial meets primary endpoint